NCT03155945View on ClinicalTrials.gov

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
Crohn's DiseaseAbdominal Pain
Interventions
DRUG

Olorinab

Olorinab active treatment for 8 weeks.

Trial Locations (7)

27612

Wake Research Associates, Raleigh

33511

Clinical Research of Brandon, Brandon

45267

University of Cincinnati Medical Center, Cincinnati

48109

University of Michigan Medical Center, Ann Arbor

60611

Northwestern University, Chicago

98405

MultiCare Institute for Research and Innovation, Tacoma

08009

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT03155945 - Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain | Biotech Hunter | Biotech Hunter